Communique of GTTAC meeting of 7 January 2021

Licence application DIR 180 from AstraZeneca Pty Ltd is for the import, transport, storage and disposal of a genetically modified (GM) COVID-19 vaccine as part of its commercial supply as a vaccine in Australia. The Committee noted that the Therapeutic Goods Administration has regulatory responsibility for evaluating the efficacy of the vaccine and patient safety.